Inaktiver Wert

Andere Sprachen Cellectar Biosciences Inc Nasdaq

Aktien

US15117F2039

Schlusskurs Nasdaq Andere Börsenplätze
- ^USD	-

29.05.	Cellectar Biosciences, Inc. und das City of Hope Cancer Center vereinbaren Zusammenarbeit zur Evaluierung von Iopofosine I 131 bei Mycosis fungoides	CI
14.05.	Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Cellectar Biosciences, Inc. and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis fungoides	29.05.
Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024	14.05.
Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
CELLECTAR BIOSCIENCES, INC. : Roth MKM favorable sur le dossier	28.03.
CELLECTAR BIOSCIENCES, INC. : Oppenheimer persiste à l'achat	28.03.
Transcript : Cellectar Biosciences, Inc., 2023 Earnings Call, Mar 27, 2024	27.03.
Cellectar Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	04.03.
Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study	30.01.
Sector Update: Health Care Stocks Advance Late Afternoon	22.01.
Cellectar Biosciences Shares Rise as Drug Shows Promise on Complete Central Nervous System Clearance on Cancer Type	22.01.
Cellectar Biosciences, Inc. Reports Complete Central Nervous System Clearance in Relapsed/Refractory Waldenstrom?s Macroglobulinemia Patient	22.01.
Transcript : Cellectar Biosciences, Inc. - Special Call	19.01.
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors and Releases Promising Preclinical Data	16.01.
Cellectar Biosciences Partners with MiBA to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting	11.01.
CELLECTAR BIOSCIENCES, INC. : Oppenheimer toujours positif	09.01.
Transcript : Cellectar Biosciences, Inc. - Special Call	08.01.
Cellectar's blood cancer therapy succeeds in late-stage study	08.01.
Cellectar's blood cancer therapy succeeds in trial	08.01.
Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia	08.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cellectar Biosciences Inc Nasdaq

Aktien

US15117F2039

Andere Sprachen

Filter